Skip to content
Home/Companies/Biotech/Galecto

Galecto

Biotech·Denmark·Exited 2020·Held 8yr
Entry
2012
Hold
8yr
Exit
2020

Who owns Galecto?

Galecto was owned by Sunstone Life Science Ventures through Sunstone Life Science Ventures III (2007 vintage) from 2012 to 2020, exited via IPO.

Hand-verified · updated 2026-08-18

Sunstone Life Science Ventures
Investor
Sunstone Life Science Ventures
Sunstone Life Science Ventures III · 2007 · VC

Key facts

HQDenmark
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2020

More from Sunstone Life Science Ventures III

Other portfolio companies in the same fund.

MinervaX
MinervaX
Active
BiotechDenmark· 2014
Cantargia
Exited 2015
BiotechSweden· 2013
Opsona Therapeutics
Exited 2019
BiotechIreland· 2013
Follicum
Exited 2014
BiotechSweden· 2012
to
Orphazyme
Orphazyme
Exited 2017
BiotechDenmark· 2011
Vaximm
Exited 2022
BiotechGermany· 2011
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Aldevron
Aldevron
Active
TA AssociatesUS
Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
Elkedonia
Elkedonia
Active
Capital Grand EstFrance
Track Galecto

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Galecto?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Galecto.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue